← Back to Search

Algorithm for Transthyretin Amyloid Cardiomyopathy

N/A
Waitlist Available
Led By Taha Bandukwala, MD
Research Sponsored by Ensho Health Intelligent Systems Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up six months
Awards & highlights
No Placebo-Only Group

Summary

This study will assess whether CA-4F can improve diagnosis of ATTR-CM in a community cardiology setting when used to screen electronic medical record data for patients suitable for follow-up investigations.

Eligible Conditions
  • Transthyretin Amyloid Cardiomyopathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~six months
This trial's timeline: 3 weeks for screening, Varies for treatment, and six months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinical utility of CA-4F
Secondary study objectives
Optimal threshold for clinical use
Other study objectives
Impacts of CA-4F on age at first diagnosis
Impacts of CA-4F on rate of diagnosis in priority subgroups

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: AlgorithmExperimental Treatment1 Intervention
All participating cardiologists.

Find a Location

Who is running the clinical trial?

Ensho Health Intelligent Systems Inc.Lead Sponsor
Taha Bandukwala, MDPrincipal InvestigatorChief Medical Officer
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top